ADARx Pharmaceuticals, Inc. (ADRX)
17.63
-0.05
(-0.28%)
USD |
NASDAQ |
Oct 23, 16:00
17.80
+0.17
(+0.96%)
After-Hours: 20:00
ADARx Pharmaceuticals Enterprise Value : 1.820B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 1.820B |
| October 22, 2026 | 1.826B |
| October 21, 2026 | 1.767B |
| October 20, 2026 | 1.826B |
| October 19, 2026 | 1.820B |
| October 16, 2026 | 1.822B |
| October 15, 2026 | 1.828B |
| October 14, 2026 | 1.842B |
| October 13, 2026 | 1.828B |
| October 12, 2026 | 1.856B |
| October 09, 2026 | 1.836B |
| Date | Value |
|---|---|
| October 08, 2026 | 1.825B |
| October 07, 2026 | 1.788B |
| October 06, 2026 | 1.922B |
| October 05, 2026 | 1.972B |
| October 02, 2026 | 1.886B |
| October 01, 2026 | 2.024B |
| September 30, 2026 | 2.067B |
| September 29, 2026 | 2.141B |
| September 28, 2026 | 2.083B |
| September 25, 2026 | 2.004B |
| September 24, 2026 | 1.753B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 7.963B |
| Oncolytics Biotech, Inc. | 58.94M |
| Sangamo Therapeutics, Inc. | 39.39M |
| Sarepta Therapeutics, Inc. | 2.130B |
| Anixa Biosciences, Inc. | 88.45M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -25.76M |
| Revenue (Quarterly) | 0.746M |
| Total Expenses (Quarterly) | 26.50M |
| EPS Diluted (Quarterly) | -0.2412 |
| Gross Profit Margin (Quarterly) | 1.47% |
| Profit Margin (Quarterly) | -3.45K% |
| Earnings Yield | -4.36% |
| Normalized Earnings Yield | -4.358 |